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Abstract 
This case report addresses diabetic peripheral neuropathic pain (DPNP), a chronic condition 
associated with diabetes mellitus. There are over 29 million people in the United States who have 
diabetes (Diabetes latest, 2014). About 25% of diabetics have pain from diabetic peripheral 
neuropathy (Snyder, Gibbs , & Lindsay, 2016). This is a very challenging and difficult condition 
to treat as it can negatively affect a person’s quality of life. This case report is based on a patient 
encounter. This is a patient who currently has diabetes, but has not been diagnosed with DPNP. I 
will examine two different treatment approaches for DPNP, pregabalin and duloxetine, and how 
effective they are in managing that pain. Pregabalin is classified as an anti-convulsant. 
Duloxetine is a serotonin norepinephrine reuptake inhibitor. Ten research articles were reviewed 
that compare the use of pregabalin and/or duloxetine in the treatment of neuropathic pain. They 
included 4 randomized clinical trials (RCTs), a meta-analysis, a systematic review, a 
retrospective chart review, a retrospective review of insurance claims, and two prospective 
studies. In every study, it was found that both duloxetine and pregabalin are effective in treating 
DPNP. However, there were contradictory findings related to the superiority of one over another. 
In one study duloxetine, did not have a direct comparison and in another pregabalin was 
compared to placebo. Three of the studies reported duloxetine superior to pregabalin. In one of 
these studies, the recommended effective dosage of pregabalin was not always given. One study 
found pregabalin superior to duloxetine. Another showed suboptimal dose of duloxetine 
compared to pregabalin. There were also four studies that included gabapentin alone or in 
combination as a treatment comparison for duloxetine and pregabalin. Side effects are common 
with both medications and one study showed more minor side effects with duloxetine. Pregabalin 
was found to have a secondary improvement in sleep. Quality evidence was found supporting the 
use of pregabalin and duloxetine for effective DPNP treatment.  
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Background 
 Millions of people throughout the world are affected by the chronic disease Diabetes 
Mellitus. It is characterized by a resistance to insulin action, inadequate disseminating 
endogenous insulin, and an insufficient compensatory insulin secretion reaction (Dunphy, 
Winland-Brown, Porter, & Thomas, 2015). Diabetes causes long-term damage and many co-
morbidities due to chronic hyperglycemia. This can affect a person’s eyes, heart, blood vessels, 
nerves, and kidneys. Macrovascular and microvascular damage is associated with long-term 
hyperglycemia. “Vascular endothelial dysfunction and inflammation result in fibrosis and intimal 
thickening, leading to progressive narrowing of the vascular lumen” (Dunphy, Winland-Brown, 
Porter, & Thomas, 2015, p. 891). This results in ischemia throughout the body due to reduced 
blood flow through the microvasculature. Common symptoms that are associated with diabetic 
peripheral neuropathy are pain, burning, allodynia, paresthesia, and hyperalgesia.  
  The purpose of this report is to address the pain and discomfort associated with peripheral 
neuropathy by examining two treatment options that are approved by the United States Food and 
Drug Administration (FDA) for treating diabetic peripheral neuropathic pain. These treatment 
options are duloxetine and pregabalin. The mechanism of action of pregabalin, an 
anticonvulsant, includes attaching to the α2-δ subunit of calcium channels in afferent neurons. 
This action decreases the release of substance P, glutamate and norepinephrine. By doing this, it 
decreases pain signals that are transmitted to the brain. Duloxetine, an antidepressant, has a 
mechanism of action that involves obstructing the reuptake of norepinephrine and serotonin in 
the central nervous system. By doing this it reduces the awareness of pain by lessening pain 
signals (Tanenberg, et al., 2011). There is an additional medication called tapentadol that is also 
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approved by the FDA for severe diabetic neuropathic pain that will not be addressed in this case 
report.  
Diabetic peripheral neuropathy and the pain associated with it is a manifestation of the 
reduced blood flow and inflammation to the microvasculature. This condition is more common 
in patients with low glycemic control and low serum insulin concentrations. The occurrence 
increases over time with diabetes. The patient may also experience a loss of sensation and 
muscle weakness. The pain associated with peripheral neuropathy can lead to mood and sleep 
disorders (Dunphy, Winland-Brown, Porter, & Thomas, 2015).   
The following case provides the background for this case report. This is a 60-year-old 
woman who has had diabetes type 2 for 10 years. Although she did not present with any 
peripheral neuropathy, the likelihood of developing this increases with time and having 
persistent hyperglycemia. The management of blood sugars is crucial with this type of patient 
and can prevent further disability down the road. By looking at what treatments and dosages are 
effective for DPNP, we can use this information to successfully treat difficult to manage chronic 
pain instead of experimenting with different treatments that are ultimately ineffective.  
Case Report 
Dorothea 60-year-old female 
CC: Diabetes recheck 
HPI: 60-year-old white female presents to the clinic today for a diabetes check-up. She was 
diagnosed with diabetes 10 years ago and has been on Metformin since her diagnosis. She states 
her diabetes is under good control and she checks her blood sugar a couple times a week and it 
usually runs in the 150-200 range. She saw the diabetes educator last week and was told she 
needed to eat better and incorporate more fruits and vegetables in her diet. She reports liking 
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sweets a lot and knows she eats too many.  She also drinks three beers two to three times a week. 
She reports walking a mile a day for exercise. The only concern she has today is that she has 
been feeling more tired the last few months. She hasn’t had any recent changes to her schedule. 
She works full-time as an information specialist at the University of North Dakota. She states she 
has been sleeping ok and getting around eight hours of sleep at night.  She denies having her 
thyroid or TSH level checked in the past.                         
Medications:                                                                                                                      
Metformin 500 mg po twice daily                                                      
Aspirin 81 mg po daily                                                                                                        
Lisinopril 20 mg po once daily                                                                               
Atorvastatin 20 mg po once daily                                                                                   







Review of Systems: 
Constitutional: No weakness, fever or night sweats 
Eyes: Patient wears glasses. She reports no blurred vision, eye pain, redness, itching, tearing, 
diplopia, flashers, floaters or light sensitivity. Last eye exam was 6 months ago.  
Ears: Reports no hearing loss, pain, discharge, tinnitus, vertigo, or fullness 
Nose: Reports no congestion, epistaxis, postnasal drip, sinus pain or pressure. 
Mouth and Throat: Reports no recent dental problems. Last saw dentist in 2016. Denies 
hoarseness, sore throat, dryness, bleeding gums or lesions. 
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Head & Neck: Reports no headaches, syncope, swollen glands, pain or neck stiffness 
Respiratory: Reports no SOB, wheezing, cough, or hemoptysis 
CV: Reports no chest pain or tightness, palpitations, edema, diaphoresis, dizziness, or orthopnea. 
Denies leg cramps or intermittent claudication.  
GI: Reports no abdominal pain, bloating, or cramping. Denies dysphagia, heartburn, dyspepsia, 
N/V, diarrhea, constipation. No blood in stool or black, tarry stool.   
GU: Denies vaginal itch, lesions. Reports no dysuria, urgency, frequency or hematuria. 
MS: No joint pain or stiffness. No swelling or motion restriction. No muscle pain.  
Neuro: No numbness or tingling to upper or lower extremities.  
Objective:  
VS: BP-148/98, P-80, RR-20, T-98.6 
Labs:  
HgbA1C- 8.5% 
Lipid panel: Cholesterol-209, LDL- 120, Triglycerides-185, HDL-33 
CMP- Normal 
TSH- Normal 
Diabetic foot exam: Sensation normal. Feet warm and dry. No open lesions or calluses present.  
General: Well -developed 60-year-old white female appearing stated age. In no acute distress. 
Alert and cooperative with exam. 
Head: Normocephalic and atraumatic without scalp or facial tenderness.  
Eyes: Conjunctivae are pink and sclera are without injection or jaundice.  
Ears: TMs shiny and pearly gray with bony landmarks and cone of light visible. No perforations 
or bulging. Canals without erythema, lesions, or excessive cerumen. Hearing grossly intact.  
Mouth: Teeth in good repair. No lesions or exudates in oropharynx or oral mucosa. Uvula rises 
midline with phonation.  
Neck: Trachea midline, thyroid not palpable. No cervical, submandibular, submental, pre-or 
post-auricular lymph nodes appreciated. Flexion, extension, and rotation without hesitation or 
limitation.  
Chest: Breath sounds clear throughout lung fields without rales, rhonchi, wheezes, or stridor 
CV: S1S2 with regular rate and rhythm. No S3, S4, murmurs, clicks or rubs 
Abdomen: Non-distended. No tenderness to palpation. Bowel sounds present all 4 quadrants.  
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MS: Full ROM to all joints without hesitation, pain, clicking, or limitation. 
Skin: Warm and dry. No rashes or lesions 
Neuro: Speech fluent. Mood euthymic with affect appropriate to situation. 
Assessment: 




1. Increase Metformin 1000 mg po twice daily.  
2. Discussed with patient that the goal is to get her HgbA1C down to < 6.0%. We will 
recheck her HgbA1C in 3 months. Patient is encouraged to reduce her intake of sweets 
and eat more fruits and vegetables and follow the recommendations from the diabetic 
educator. She is encouraged to keep exercising daily. Patient is agreeable to this.  
3. Lisinopril/Hydrochlorothiazide (HCTZ) 20 mg/12.5 mg po once daily. 
4. Discussed with patient that I would like her to purchase a blood pressure monitor and 
check her BP a couple of times a week and record. Then follow-up with me in 1 month to 
reassess if we can continue with the current blood pressure medication or if we need to 
add on a second medication. Patient is agreeable to this.  
5. Increase Atorvastatin 40 mg po once daily. Discussed with patient that her Triglycerides 
are still elevated and her HDL is lower than what I would like it to be. Hopefully with her 
diet changes and increased medication this will improve. We will recheck her Lipids at 
her 3-month follow-up. 
6. Patient is to return to the clinic or follow-up sooner than 1 month with any other 
questions or concerns.  
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Literature Review 
 The following is a review of the current literature related to the efficacy of treatment for 
DPNP with the medications pregabalin and duloxetine in adult patients. Pregabalin and 
duloxetine are currently two of three medications approved for treatment of DPNP by the FDA. 
The third medication is tapentadol extended release for severe DPNP. Pregabalin is classified as 
an anti-convulsant and is indicated for neuropathic pain, fibromyalgia, and post-herpetic 
neuralgia.  Duloxetine is classified as a serotonin-norepinephrine reuptake inhibitor and is 
indicated for depression, generalized anxiety disorder, fibromyalgia, musculoskeletal pain, and 
neuropathic pain. There have been numerous clinical trials examining the effectiveness of 
pregabalin and duloxetine for treating DPNP. Some of these studies included additional 
medications as comparisons. Gabapentin is one of those medications along with amitriptyline.  
Lunn, Hughes, and Wiffen conducted a systematic review that looked specifically at 
duloxetine for treating neuropathic pain, in addition to fibromyalgia and chronic pain. Eighteen 
trials with a total of 6407 participants were identified. They reviewed eight published studies 
with 2728 adult patients with diabetic neuropathic pain (2014). They found that there was 
moderate quality of evidence that the use of duloxetine in daily dosages of 60 mg and 120 mg 
were effective for treating painful diabetic peripheral neuropathy (PDPN). However, lower 
dosages were not effective. The review also concluded that minor side effects were common 
with the duloxetine dosages of 60 mg and more specifically with the 120-mg dosage. These 
minor side effects included headache, dry mouth, feeling sick, too sleepy or too awake, 
dizziness, and constipation. One out of 6 people discontinued duloxetine due to side effects. 
(Lunn, Hughes, & Wiffen, 2014).  
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Three randomized, double-blind and comparable 13-16 week trials were conducted to 
determine pregabalin efficacy in treating diabetic peripheral neuropathy (DPN), post-herpetic 
neuralgia, and spinal cord injury. The randomized control trials (RCTs) included a 52-week 
expansion trial. Participants in the DPN RCT received dosages of either 300 mg or 600 mg a day 
or a placebo. This was administered over twelve weeks after a week of titration. The patients 
selected had moderate to severe pain with a chronic, unrelenting neuropathic pain (Ogawa, 
Arakawa, Hayakawa, & Yoshiyama, 2016). They found considerable pain improvement after 
one week. This improvement lasted the extent of the trial. It was concluded that in treating 
central and neuropathic pain, pregabalin was repeatedly effective.  Additionally, it was found 
that pregabalin improved sleep disorder scores compared to the placebo after one week. They 
also found that in the peripheral pain trials, patients that withdrew from the trial due to side 
effects related to treatment was somewhat higher than in the comparable studies. This was 
attributed to the two different dosage regimens.  
A retrospective analysis done by Yang, Qian, and Liu studied health insurance claims 
from 2006-2011 in the United States to further examine DPNP treatment models. Out of the 
12,074 patients, 21.6% were given pregabalin, 45% were given gabapentin and 5.2% started 
duloxetine. There were also 20 patients that were prescribed a combination of duloxetine and 
pregabalin. The recommended doses per the FDA are up to 300 mg a day for pregabalin and 60 
mg a day for duloxetine. “More than 60% of duloxetine-treated patients were receiving the 
recommended dose, although 31.0% were receiving just 30 mg/day. Patients treated with 
pregabalin (91.3%) received less than 300 mg/day” (Yang, Qian, & Liu, 2015, p. 2079). Often, 
patients received less than the recommended dosage. Of the patients that received pregabalin, 
55% received 150 mg/day and sometimes even lower dosages. This despite clinical evidence 
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showing that dosages this low are comparable to receiving a placebo and do nothing for 
symptom control.  Anticonvulsants are the most frequently prescribed medications for DPNP for 
those patients that are newly diagnosed, however these medications were often discontinued 
early.  It was also found that within three months of medication initiation, 50% of patients 
discontinued their prescription. The one-year discontinuation rates for duloxetine-64.4%, and 
pregabalin-76.7% (Yang, Qian, & Liu, 2015).  
A prospective observational 6-month study that included 2575 patients examined the 
effectiveness of pregabalin, duloxetine and gabapentin on DPNP (Happich, et al., 2014). They 
found that younger patients switched to or started duloxetine. These patients also worked for pay 
more often and had higher alcohol intake. They were more often receiving treatment from a 
general practitioner and not a neurologist. They more frequently had depression and type 2 
diabetes. They had previous treatment with other antidepressants, non-opioid analgesics and 
opioids. They also had more disease-related problems, more severe pain, and poor mental health. 
They found that patients treated with pregabalin and gabapentin were not treated with 
appropriate dosages. This could explain the outcomes of the study, that patients treated with 
duloxetine showed substantially superior improvements in efficacy measures than those treated 
with gabapentin or pregabalin. The duloxetine patients often received recommended dosages 
with an average daily dosage of 53.9 mg. The average daily dosage of pregabalin was 173.5 mg 
(Happich, et al., 2014). This contrasted with the previous study from Yang et. al. that showed 
suboptimal dosages of duloxetine were used for treating DPNP (2015). 
A prospective 6-month study done by Roy et al., not only compared the efficacy of 
duloxetine and pregabalin, but also examined the cost effectiveness of both medications for 
treating DPNP. The study was conducted in a diabetic clinic in South India. The patients were 
EFFECTIVENESS OF DULOXETINE AND PREGABALIN IN DIABETIC 12 
 
not previously treated with either drug. Fifty patients were treated with pregabalin and 50 
patients were treated with duloxetine. The Neuropathic Pain Scale and the Neuro-Qol 
questionnaires were used to assess patient’s pain. In treating neuropathic pain, duloxetine was 
found to be more effective than pregabalin, but was more expensive. However, both medications 
were shown to significantly reduce DPNP. Fourteen patients dropped out that were taking 
duloxetine and 2 that were taking pregabalin. The discontinuation was due to a combination of 
adverse events, cost, alternative therapy, and termination of treatment (Roy, Kuriakose, Varma, 
& Jacob, 2017). 
A double-blind RCT done by Boyle et al. (2012), examined the pain-relieving efficacy of 
duloxetine, pregabalin, and amitriptyline along with their secondary effect on sleep, quality of 
life and daytime functioning in patients with DPNP. This secondary effect on mood and sleep 
may play a part in the successful treatment of patients with DPNP. Between February 2007 and 
March 2009, 83 subjects with diabetes type 1 and 2 participated in the study. Twenty-seven were 
given pregabalin, 28 amitriptyline, and 28 duloxetine. When compared with placebo, pregabalin, 
duloxetine and amitriptyline all reduced pain with not one medication better than another. There 
was a 50% improvement in subjective pain which is comparable to similar studies. As far as 
sleep continuity, there was a pronounced reduction in REM sleep and sleep was very disjointed 
with duloxetine, but duloxetine did improve performance on sensory motor tasks and improved 
central nervous system stimulation (Boyle, et al., 2012).  Whereas, pregabalin stimulated sleep. 
As far as medication effects on daytime activity function, it was comparatively ineffective. A 
higher number of side effects also were found in the subjects treated with pregabalin. 
One RCT examined patients that were originally treated with gabapentin >= 900 mg/day 
for DPNP and had an unsatisfactory response with a pain score >=4 using a 0-10 pain scale. 
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These patients were then randomized to be treated with either pregabalin (n=134), duloxetine 
(n=138), or a combination of gabapentin and duloxetine (n=135).  The purpose of this study was 
to determine if treatment with duloxetine was substandard in comparison to treatment with 
pregabalin. The duloxetine dosage was titrated up to 60 mg/day after one week. The pregabalin 
dosage was titrated up to 300 mg/day after one week. The third group treated with a combination 
of gabapentin/duloxetine remained on the initial dosage of gabapentin >=900 mg/day in addition 
to titrating the dosage of duloxetine up to 60 mg/day. Researchers reported that considerably 
more patients discontinued the duloxetine (n=27) due to side effects than with the pregabalin or 
the gabapentin/duloxetine combination. These side effects included, nausea, decreased appetite, 
excessive perspiration, and insomnia. However, peripheral edema was greater with the use of 
pregabalin. Researchers concluded that treatment with duloxetine was non-inferior to pregabalin 
and gabapentin/duloxetine for DPNP. They also found that adding duloxetine to the gabapentin 
was effective in treating DPNP similar to using pregabalin or duloxetine alone. (Tanenberg, et 
al., 2011).  
A randomized, double-blind COMBO-DN study examined the Neuropathic Pain 
Symptom Inventory (NPSI) of patients initially to determine a baseline, then after either 
pregabalin or duloxetine therapy for eight weeks, and then again after an eight-week increased 
dose/combination therapy. The study also showed that diabetic patients present with differing 
sensory profiles in their response to pain. The initial therapy was 300 mg pregabalin or 60 mg 
duloxetine. If patients had <30% improvement, then the patients receiving duloxetine, increased 
to 120 mg and patients receiving pregabalin increased to 600 mg or a combination of 300 mg 
pregabalin and 60 mg duloxetine. In the primary therapy duloxetine worked better for pain. “The 
present exploratory analyses of data collected in the COMBO-DN study suggest that duloxetine 
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and pregabalin have different effects on distinct neuropathic pain components in diabetic 
peripheral neuropathy” (Bouhassira, et al., 2014, p. 2174). In patients not responding to the 
initial monotherapy of duloxetine, the combination of duloxetine and pregabalin was favorable in 
patients with persistent and induced pain. In patients where dysesthesia/paresthesia is 
pronounced, increasing the duloxetine to 120 mg/day was more advantageous (Bouhassira, et al., 
2014). 
A meta-analysis was used to examine the tolerability and effectiveness of duloxetine to 
pregabalin and gabapentin compared with a placebo in treating DPNP. A total of eleven RCTs 
were reviewed, with 3 studies on duloxetine, 6 on pregabalin, and 2 on gabapentin. A 24-hour 
average pain severity was used to assess treatment effectiveness. Duloxetine, pregabalin and 
gabapentin were found to be exceptional compared to the placebo. Duloxetine was associated 
with more incidences of nausea, headache, dizziness, and sleepiness. It also had greater 
occurrences of discontinuation compared to placebo. This was a similar case with pregabalin. 
Pregabalin was associated with somnolescence and dizziness along with greater discontinuation 
compared to placebo. In the direct comparison of pregabalin and duloxetine, three effectiveness 
outcomes were considered; seven tolerability outcomes, 24-hour pain severity, and Patient 
Global Impression of Improvement/Change (PGI-I/C). There was found to be no difference in 
24-hour PS between pregabalin and duloxetine. It was found that the PGI-I/C was preferential to 
pregabalin, and duloxetine was preferred in the tolerability outcomes (Quilici, et al., 2009). 
A retrospective chart review done in a neuromuscular outpatient clinic examined the use 
of duloxetine and pregabalin for diabetic neuropathic pain (DNP) over a 10-month period. In 
addition, the chart review examined the effect of these two medications on cryptogenic sensory 
polyneuropathy. This is a common type of neuropathy seen in patients over 50 years of age. One 
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hundred and three patients were started on duloxetine and 91 patients were started on pregabalin. 
Those patients taking pregabalin (33%) conveyed a greater improvement in neuropathic pain 
compared to the patients taking duloxetine (21%). Compared to pregabalin (30%), duloxetine 
(38%) had more reported side effects. There were no significant differences between duloxetine 
and gabapentin. This retrospective review suggests that duloxetine and pregabalin would both be 
effective in treating DPN secondary to either cryptogenic sensory polyneuropathy or diabetes 
mellitus. (Mittal, et al., 2011).  
 
Learning Points 
When using the recommended doses of pregabalin and duloxetine, both are very effective 
medications to use for DPNP. However, when providers prescribe ineffective dosages of these 
medications, they do not work and lead patients to discontinue these medications preemptively.  
Duloxetine and pregabalin have minor side effects that many patients are unable to 
tolerate. They may discontinue these medications early due to these side effects. Having patients 
use the lowest recommended dosage for both medications may lessen the chance of developing 
adverse drug reactions as the side effects increase with an increase in dosage. 
Pregabalin was found to improve patient’s sleep in addition to DPNP in one study. This 
secondary component might improve the patient’s overall well-being, quality of life, and level of 
functioning. Further studies would be warranted.  
One study found that both medications have different effects on neuropathic pain 
components. The examination of a patient’s unique sensory profiles in response to pain could 
provide more accurate information for future treatment options. This finding would also benefit 
from replication.  
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